Showing results (311-320 of 400) with videos related to

Sort By:
Pageof 40
Leukemia|July 16, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final resultsJorge E Cortes, Delphine Rea, Michael J Mauro, et al.
Blood|November 23, 2020
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALLPraveen Anand, Amy Guillaumet-Adkins, Valeriya Dimitrova, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.
Leukemia|February 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasmsBenjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2018
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung CancerShuai Li, Shengwu Liu, Jiehui Deng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2024
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA ProfilingTalal El Zarif, Catherine B Meador, Xintao Qiu, et al.
Cancer Discovery|January 16, 2024
TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, Haritha Mathsyaraja, Marco Campisi, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Pageof 40